ODI Pharma’s new share issue prior to listing significantly oversubscribed
The subscription period in ODI Pharma AB's ("ODI Pharma" or "Company") new share issue prior to listing on Spotlight Stock Market was completed on the 30th of December 2019. The interest was significant, and the Company today announces that the new share issue of a maximum of approximately SEK 25 million was subscribed to approximately 383 percent (incl. pre-subscription commitments), which means that ODI Pharma will receive approximately SEK 25 million before issue costs. The offering that was made available for the public (i.e. not incl. pre-subscription commitments), which represented